Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,464 active trials11 approved drugs128 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07209449 | A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer | recruiting | Phase 2 | 75 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06129604 | Pilot Window of Opportunity Trial (POET) | active not recruiting | Phase 2 | 10 | University of OklahomaOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06533059 |
| A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors |
| active not recruiting |
| Phase 1 |
| 110 |
| Alterome Therapeutics, Inc.INDUSTRY |
| 8 |
| Jul 15, 2026 |
| clinicaltrials |
| NCT07220512 | The Better, Harder, Faster, Stronger Study | recruiting | — | 35 | Wake Forest University Health SciencesOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT01116648 | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 155 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2026 | clinicaltrials |
| NCT04606914 | Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer | recruiting | Phase 2 | 70 | University of Alabama at BirminghamOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05804370 | Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302) | recruiting | Phase 3 | 170 | NX Development CorpINDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07622901 | Fasting InTervention for Endometrial Cancer(FIT-ENDO) | recruiting | N/A | 42 | University of MiamiOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07702721 | Intraoperative Microscopic Assessment of Lymph Node Status in Gynecological Malignancies(IMAGINE) | not yet recruiting | — | 160 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Jul 14, 2026 | clinicaltrials |
| NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | recruiting | Phase 1 / Phase 2 | 29 | University of FloridaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05057715 | huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer | active not recruiting | Phase 1 | 13 | University of PennsylvaniaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05787587 | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 216 | IDEAYA BiosciencesINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05887609 | An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib | recruiting | Phase 2 | 53 | University of Colorado, DenverOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07139977 | Study of EV for Recurrent Endometrial Carcinoma(EV-4-EC) | recruiting | Phase 2 | 12 | William BradleyOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07322094 | CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 60 | TORL Biotherapeutics, LLCINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07693452 | Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms | recruiting | Phase 2 | 15 | University of California, IrvineOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04830709 | Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer(SCOUT-1) | active not recruiting | — | 752 | AstraZenecaINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | recruiting | Phase 2 | 200 | Jazz PharmaceuticalsINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT06834204 | Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors(ACCESS-PC) | enrolling by invitation | N/A | 266 | Rutgers, The State University of New JerseyOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06997029 | A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors | recruiting | Phase 1 | 234 | Bristol-Myers SquibbINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT07637851 | Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer(RegeNovar) | not yet recruiting | Phase 1 / Phase 2 | 43 | ARCAGY/ GINECO GROUPOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07696169 | Disease Evolution and Risk Factors of AIDS-related Prevalent Cancers | not yet recruiting | — | 1,000 | Shenzhen Third People's HospitalOTHER | 0 | Jul 10, 2026 | clinicaltrials |
| NCT04774419 | Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery | recruiting | Phase 2 | 62 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07527143 | Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer | recruiting | — | 25 | Mayo ClinicOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07693894 | DISARM Clinical Study B: Evaluation of Innovative Ovarian Cancer Biomarker Assays(DISARM CSB) | not yet recruiting | — | 2,080 | National and Kapodistrian University of AthensOTHER | 0 | Jul 9, 2026 | clinicaltrials |
| NCT02650986 | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | active not recruiting | Phase 1 / Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT03587311 | Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 | 96 | National Cancer Institute (NCI)NIH | 2 | Jul 8, 2026 | clinicaltrials |
| NCT05942300 | CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer | recruiting | Phase 1 | 30 | Lan CoffmanOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07070726 | UNTOLD Ovarian Cancer Unmet Needs Survey | recruiting | — | 2,000 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07296887 | CARE Tool Study Aim 3 | recruiting | N/A | 430 | Washington University School of MedicineOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07690540 | DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER(iDEA) | recruiting | N/A | 510 | European Institute of OncologyOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT01883297 | "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 1 | 3 | University Health Network, TorontoOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT02956031 | Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women.(DiaVACCS) | recruiting | — | 1,500 | University of PretoriaOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT03737643 | Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients(DUO-O) | active not recruiting | Phase 3 | 1,407 | AstraZenecaINDUSTRY | 20 | Jul 7, 2026 | clinicaltrials |
| NCT05581121 | PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer(PAROLA) | recruiting | Phase 3 | 510 | Institut Claudius RegaudOTHER | 4 | Jul 7, 2026 | clinicaltrials |
| NCT06611540 | Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03) | active not recruiting | N/A | 500 | National Cancer Institute (NCI)NIH | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06611553 | Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02) | active not recruiting | N/A | 500 | National Cancer Institute (NCI)NIH | 2 | Jul 7, 2026 | clinicaltrials |
| NCT06994195 | A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) | recruiting | Phase 3 | 450 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07676461 | Oral, Fecal and Intratumoral Microbiome Atlas in Colombian Patients With Advanced Solid Tumors Receiving First-Line Immunotherapy(ATLAS) | recruiting | — | 150 | Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento AnguloOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06710756 | Lead-212 PSV359 Therapy for Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 112 | Perspective TherapeuticsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07226427 | A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer | recruiting | Phase 1 | 100 | Stemline Therapeutics, Inc.INDUSTRY | 3 | Jul 6, 2026 | clinicaltrials |
| NCT07406087 | Navigation Intervention for Adolescent and Young Adult Cancer Survivors | recruiting | N/A | 25 | Kaiser PermanenteOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07643012 | Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer(ADAPT-EC) | recruiting | N/A | 30 | Rutgers, The State University of New JerseyOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04214067 | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer | active not recruiting | Phase 3 | 164 | National Cancer Institute (NCI)NIH | 2 | Jul 2, 2026 | clinicaltrials |
| NCT06819007 | Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)(DO-01) | recruiting | Phase 3 | 582 | Daiichi SankyoINDUSTRY | 25 | Jul 2, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07169734 | A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Alentis Therapeutics AGINDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT07436793 | Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial | recruiting | Phase 2 | 140 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07671937 | INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study(INSPIRE) | not yet recruiting | N/A | 2,748 | University of Alabama at BirminghamOTHER | 1 | Jul 2, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jul 16, 2026source: clinicaltrials